Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Different Materials for Plugging a Dehiscent Superior Semicircular Canal: A Comparative Histologic Study Using a Gerbil Model.

Kwok P, Gleich O, Spruss T, Strutz J.

Otol Neurotol. 2019 Jun;40(5):e532-e541. doi: 10.1097/MAO.0000000000002205.

PMID:
31083091
2.

MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma.

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK.

Pigment Cell Melanoma Res. 2018 Sep;31(5):614-629. doi: 10.1111/pcmr.12698. Epub 2018 Mar 25.

PMID:
29495114
3.

Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.

Dietrich P, Kuphal S, Spruss T, Hellerbrand C, Bosserhoff AK.

Oncogene. 2018 Feb 15;37(7):897-911. doi: 10.1038/onc.2017.391. Epub 2017 Oct 23.

PMID:
29059159
4.

Efficient Transformation of Primary Human Mesenchymal Stromal Cells by Adenovirus Early Region 1 Oncogenes.

Speiseder T, Hofmann-Sieber H, Rodríguez E, Schellenberg A, Akyüz N, Dierlamm J, Spruss T, Lange C, Dobner T.

J Virol. 2016 Dec 16;91(1). pii: e01782-16. doi: 10.1128/JVI.01782-16. Print 2017 Jan 1.

5.

Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma.

Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, Weiss TS, Oefner PJ, Müller M, Bosserhoff AK, Hellerbrand C.

Carcinogenesis. 2014 Jun;35(6):1407-15. doi: 10.1093/carcin/bgu054. Epub 2014 Mar 3.

6.

Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition.

Schmidt J, Riechers A, Stoll R, Amann T, Fink F, Spruss T, Gronwald W, König B, Hellerbrand C, Bosserhoff AK.

PLoS One. 2012;7(5):e37941. doi: 10.1371/journal.pone.0037941. Epub 2012 May 29.

7.

Liver regeneration associated protein (ALR) exhibits antimetastatic potential in hepatocellular carcinoma.

Dayoub R, Wagner H, Bataille F, Stöltzing O, Spruss T, Buechler C, Schlitt HJ, Weiss TS.

Mol Med. 2011 Mar-Apr;17(3-4):221-8. doi: 10.2119/molmed.2010.00117. Epub 2010 Dec 8.

8.

Adenovirus type 5 early encoded proteins of the E1 and E4 regions induce oncogenic transformation of primary rabbit cells.

Wimmer P, Täuber B, Spruss T, Dobner T.

J Gen Virol. 2010 Jul;91(Pt 7):1828-33. doi: 10.1099/vir.0.020537-0. Epub 2010 Mar 24.

PMID:
20335490
9.

Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

Amann T, Bataille F, Spruss T, Dettmer K, Wild P, Liedtke C, Mühlbauer M, Kiefer P, Oefner PJ, Trautwein C, Bosserhoff AK, Hellerbrand C.

Am J Pathol. 2010 Mar;176(3):1433-42. doi: 10.2353/ajpath.2010.090356. Epub 2010 Jan 21.

10.

Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma.

Amann T, Bataille F, Spruss T, Mühlbauer M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK, Hellerbrand C.

Cancer Sci. 2009 Apr;100(4):646-53. doi: 10.1111/j.1349-7006.2009.01087.x. Epub 2009 Jan 21.

11.

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma.

Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, Pfeifer A, Fässler R, Bosserhoff AK.

J Exp Med. 2009 Jan 16;206(1):221-32. doi: 10.1084/jem.20082044. Epub 2009 Jan 5.

12.

In vivo development and long-term survival of engineered adipose tissue depend on in vitro precultivation strategy.

Weiser B, Prantl L, Schubert TE, Zellner J, Fischbach-Teschl C, Spruss T, Seitz AK, Tessmar J, Goepferich A, Blunk T.

Tissue Eng Part A. 2008 Feb;14(2):275-84. doi: 10.1089/tea.2007.0130.

PMID:
18333780
13.

Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Hubensack M, Müller C, Höcherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A.

J Cancer Res Clin Oncol. 2008 May;134(5):597-607. Epub 2007 Oct 12.

PMID:
17932689
14.

The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma.

Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, Hartmann A, Bosserhoff AK.

Gut. 2008 Feb;57(2):243-51. Epub 2007 Sep 19.

PMID:
17881540
15.

Inhibition of Smad7, a negative regulator of TGF-beta signaling, suppresses autoimmune encephalomyelitis.

Kleiter I, Pedré X, Mueller AM, Poeschl P, Couillard-Despres S, Spruss T, Bogdahn U, Giegerich G, Steinbrecher A.

J Neuroimmunol. 2007 Jul;187(1-2):61-73. Epub 2007 Jun 5.

PMID:
17553571
16.

Functional implication of BMP4 expression on angiogenesis in malignant melanoma.

Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK.

Oncogene. 2007 Jun 14;26(28):4158-70. Epub 2006 Dec 18.

PMID:
17173062
17.

CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity.

Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, Tan TE, Lim YC, Schwarz H.

FASEB J. 2007 Feb;21(2):456-63. Epub 2006 Dec 13.

PMID:
17167064
18.

Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.

Schertl S, Hartmann RW, Batzl-Hartmann C, Spruss T, Maucher A, von Angerer E, Schiller CD, Schneider MR, Gust R, Schönenberger H.

J Cancer Res Clin Oncol. 2007 Mar;133(3):153-67. Epub 2006 Oct 6.

PMID:
17024493
19.

Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids.

Guse C, Koennings S, Maschke A, Hacker M, Becker C, Schreiner S, Blunk T, Spruss T, Goepferich A.

Int J Pharm. 2006 May 18;314(2):153-60. Epub 2006 Mar 6.

PMID:
16517106
20.

Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion.

Gürtler U, Fuchs P, Stangelmayer A, Bernhardt G, Buschauer A, Spruss T.

Arch Pharm (Weinheim). 2004 Dec;337(12):672-81.

PMID:
15597400
21.
22.

Generation of mature fat pads in vitro and in vivo utilizing 3-D long-term culture of 3T3-L1 preadipocytes.

Fischbach C, Spruss T, Weiser B, Neubauer M, Becker C, Hacker M, Göpferich A, Blunk T.

Exp Cell Res. 2004 Oct 15;300(1):54-64.

PMID:
15383314
23.
24.

[1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.

Schertl S, Hartmann RW, Batzl-Hartmann C, Bernhardt G, Spruss T, Beckenlehner K, Koch M, Krauser R, Schlemmer R, Gust R, Schönenberger H.

Arch Pharm (Weinheim). 2004 Jun;337(6):335-48.

PMID:
15188223
25.

External carotid artery territory ischemia impairs outcome in the endovascular filament model of middle cerebral artery occlusion in rats.

Dittmar M, Spruss T, Schuierer G, Horn M.

Stroke. 2003 Sep;34(9):2252-7. Epub 2003 Jul 31.

PMID:
12893948
26.

Monolithic triglyceride matrices: a controlled-release system for proteins.

Vogelhuber W, Magni E, Mouro M, Spruss T, Guse C, Gazzaniga A, Göpferich A.

Pharm Dev Technol. 2003;8(1):71-9.

PMID:
12665199
27.

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G.

J Clin Invest. 2002 Nov;110(9):1309-18.

28.

Establishment and characterization of new murine breast cancer cell lines.

Bernhardt G, Beckenlehner K, Spruss T, Schlemmer R, Reile H, Schönenberger H.

Arch Pharm (Weinheim). 2002 Mar;335(2-3):55-68.

PMID:
12043456
29.

Establishment and Characterization of New Murine Breast Cancer Cell Lines.

Bernhardt G, Beckenlehner K, Spruss T, Schlemmer R, Reile H, Schönenberger H.

Arch Pharm (Weinheim). 2002 May;335(2):55-68.

PMID:
12007108
30.

Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts.

Vogelhuber W, Spruss T, Bernhardt G, Buschauer A, Göpferich A.

Int J Pharm. 2002 May 15;238(1-2):111-21.

PMID:
11996815
32.

The induction of micronuclei in vitro by unpolymerized resin monomers.

Schweikl H, Schmalz G, Spruss T.

J Dent Res. 2001 Jul;80(7):1615-20.

PMID:
11597020
33.

1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.

Schertl S, Hartmann RW, Batzl-Hartmann C, Schlemmer R, Spruss T, Bernhardt G, Gust R, Schönenberger H.

Arch Pharm (Weinheim). 2001 Apr;334(4):125-37.

PMID:
11382148
34.

Programmable biodegradable implants.

Vogelhuber W, Rotunno P, Magni E, Gazzaniga A, Spruss T, Bernhardt G, Buschauer A, Göpferich A.

J Control Release. 2001 May 18;73(1):75-88.

PMID:
11337061
35.

"Hit-and-run" transformation by adenovirus oncogenes.

Nevels M, Täuber B, Spruss T, Wolf H, Dobner T.

J Virol. 2001 Apr;75(7):3089-94.

38.

Two distinct activities contribute to the oncogenic potential of the adenovirus type 5 E4orf6 protein.

Nevels M, Rubenwolf S, Spruss T, Wolf H, Dobner T.

J Virol. 2000 Jun;74(11):5168-81.

39.

Establishment and characterization of the follicular thyroid carcinoma cell line ML-1.

Schönberger J, Bauer J, Spruss T, Weber G, Chahoud I, Eilles C, Grimm D.

J Mol Med (Berl). 2000;78(2):102-10.

PMID:
10794546
41.

Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice.

Orsó E, Broccardo C, Kaminski WE, Böttcher A, Liebisch G, Drobnik W, Götz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani MF, Rothe G, Lackner KJ, Chimini G, Schmitz G.

Nat Genet. 2000 Feb;24(2):192-6.

PMID:
10655069
42.

[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] sulfatoplatinum(II)--pharmacokinetic studies.

Bernhardt G, Koch M, Spruss T, Gust R, Krauser R, Schlemmer R, Hollstein M, Lux F, Schönenberger H.

Arch Pharm (Weinheim). 1999 Jun;332(6):195-200.

PMID:
10399488
45.

Transforming potential of the adenovirus type 5 E4orf3 protein.

Nevels M, Täuber B, Kremmer E, Spruss T, Wolf H, Dobner T.

J Virol. 1999 Feb;73(2):1591-600.

47.

Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers.

Muckenschnabel I, Bernhardt G, Spruss T, Dietl B, Buschauer A.

Cancer Lett. 1998 Sep 11;131(1):13-20.

PMID:
9839615
48.

The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function.

Nevels M, Rubenwolf S, Spruss T, Wolf H, Dobner T.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1206-11.

49.

Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice.

Muckenschnabel I, Bernhardt G, Spruss T, Buschauer A.

Cancer Chemother Pharmacol. 1996;38(1):88-94.

PMID:
8603457
50.

Supplemental Content

Loading ...
Support Center